10X Genomics Hits New 52-Week High at $31.15, Reflecting Strong Growth

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 31.15 on June 2, 2026. This achievement underscores the company's notable performance over the past year, with a remarkable increase of 38.46%, significantly outpacing the S&P 500's growth of 28.2% during the same period. With a market capitalization of USD 2,132 million, 10X Genomics operates in a competitive industry characterized by innovation and rapid advancements. Despite being a loss-making entity, the company maintains a price-to-book ratio of 2.68, indicating its valuation relative to its assets. The firm currently does not offer a dividend, and its debt-to-equity ratio stands at -0.64, reflecting a unique financial structure. The stock's journey from a 52-week low of USD 8.95 to its current high illustrates the volatility and potential within the biotechnology space. As 10X Genomics continues to navigate the complexities of its industry, this new price point marks a noteworthy achievement in its financial trajectory.